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Abstract
Introduction and objective. As the autonomic nervous system (ANS) dysfunction is present in course of many disorders, 
an objective assessment of the ANS function is very important. In practice, the assessment is difficult, and based rather 
on indirect analysis of autonomically-controlled cardiovascular reflexes, than on direct recording of activity of central or 
peripheral autonomic structures.  
The aim of our paper was to discuss briefly current, clinical and scientific ANS investigations, as well as possible future 
methods of autonomic activity evaluation.  
A brief description of the state of knowledge. The review presents a short outline of autonomic function assessments 
based on clinical autonomic tests (e.g. “Ewing’s battery”) and discusses the heart rate variability (HRV) study, as currently 
popular and widespread option of analysis of the ANS activity. Other, complementary methods, including the baroreceptor 
sensitivity testing, microneurography or plasma norepinephrine measurement were also mentioned. The article also 
provides premises related to the determination of selected neuropeptides in plasma or saliva as an innovative concept of 
autonomic activity assessment.  
Summary. The available, clinical, non-invasive methods used for assessment of the ANS function are still relatively sparse 
and, in fact, a surrogate for direct ANS assessment. New methods of autonomic tension determination are still needed that 
would allow a more complete and reliable assessment. Reports of potential new laboratory markers of the ANS activity 
(NPY and VIP assay) bring some hope.
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INTRODUCTION AND OBJECTIVE
Organization of the autonomic nervous system. The 
autonomic nervous system (ANS) supplies all organs and, 
together with the endocrine and the immunological systems, 
it is responsible for the regulation and integration of body 
function. The ANS, with the above-mentioned systems, 
controls body homeostasis, which means a dynamic 
adjustment of physiological activity to the continuously 
changing external and internal environment, to adapt 
the body to the current needs [1, 2, 3]. Homeostasis is 
an involuntary phenomenon, occurring usually through 
a system of negative feedback, involving the central and 
peripheral autonomic structures.
Anatomically the ANS is divided into two parts: the 
sympathetic (adrenergic) and parasympathetic (cholinergic) 
systems. The sympathetic component originates from central 
neurons located in the front area of the ventro-lateral part 
of the medulla oblongata (RVLM – rostral ventrolateral 
medulla), gigantocellular nucleus, raphe nuclei, adrenergic 
area of the brain pons and the paraventricular hypothalamic 
nucleus. They are regarded to be specific pacemakers, 
tonically controlling sympathetic, pre-ganglionic neurons 
in the gray matter of the spinal cord (segments Th1-Th12 
and L1-L3) in response to afferent signals reaching the 
brain. Postganglionic, sympathetic fibres, supplying target 
organs and releasing noradrenaline (NA) as the main 
neurotransmitter, originate from the paravertebral ganglia 
creating symmetric sympathetic trunks.
The parasympathetic (PS) ANS part involves the central 
structure (located above the RVLM), at the back of the ventro-
medial medulla area, neurons constituting the CVLM (caudal 
ventrolateral medulla) centre, as well as other structures: 
nucleus of the solitary tract, periaqueductal gray and spinal 
cord (segments S2-S4). The CVLM interacts with central 
sympathetic components, and – on one hand – inhibits 
their activity, and on the other, stimulates the preganglionic 
parasympathetic fibres originating from other centrally-
located PS structures. The parasympathetic, intramural 
ganglia give rise to postganglionic fibres in terminal organs. 
The most important parasympathetic innervation involves 
vagus nerve branches, supplying both chest and abdomen 
via the acetylcholine (Ach) release [2, 4]
Primary and secondary autonomic disorders and 
symptoms of dysautonomia. The ANS dysfunction results 
from both primary disorders, directly affecting ANS, and 
from multiple and diverse diseases affecting other organs, 
where they trigger pathological autonomic disturbances 
[3]. Examples of clinical entities associated with autonomic 
dysfunction are given in the Table 1.
There are also many drugs that influence autonomic 
function, either by their impact on adrenergic or cholinergic 
receptors or by other, miscellaneous mechanisms. The most 
important ones are also shown in Table 1.
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An autonomic insufficiency may result in dysfunction of 
selected organs, but most symptoms of dysautonomia are 
non-characteristic and have a pleiotropic character, involving 
clinical manifestations from various systems. An autonomic 
dysfunction may manifest either in the ANS failure or in its 
over-activity. The most significant signs and symptoms of 
autonomic dysfunction are summarized in Table 2.
Taking into consideration the diversity of clinical symptoms 
of dysautonomia (being a result of many different diseases 
mentioned above, as well as a possible, etiologic factor of 
other secondary disorders), it is important to be able to assess 
the ANS functional status in an reliable and objective way.
DESCRIPTION OF THE STATE OF KNOWLEDGE
ANS function assessment is difficult, considering the fact 
that, in practice, there is no direct method of inspection 
of the autonomic innervation. For this reason, an indirect 
assessment has to be performed, based on observation of 
autonomically-mediated reflexes in a patient. The fact that 
the ANS function is continuously modulated by a number 
of external as well as internal factors, of both physiological 
(stress, exercise, food, stimulants) and pathological nature 
(co-existing disturbances, drugs) is an additional difficulty. 
For these reasons, the assessment of the functional ANS 
state is difficult and time consuming, requires development 
and standardization of procedures, and is a very important 
element in the patient’s pathophysiological description.
In the complex evaluation of the ANS activity, some 
widely-known, routine clinical methods are used, although 
less commonly performed scientific methods may also be 
applied. Some laboratory attempts at autonomic activity 
assessments are additionally mentioned in research studies. 
However, at present, they are believed to be only experimental 
methods of no well-established importance and they require 
further analysis regarding their suitability.
Medical interview and physical examination in 
dysautonomia. Clinical evaluation of a patient’s autonomic 
nervous system is based on detailed anamnesis and physical 
examination, focusing on the detection of potential 
symptoms of dysautonomia listed above (Tab. 2). In the 
medical interview, questions concerning cardiac, vasomotor 
and gastrointestinal disturbances, bladder dysfunction or 
sexual dysfunction are of special interest [5]. The differential 
diagnosis targeted on diseases is important (Tab. 1). The 
quantitative dysautonomia symptom assessment is possible 
using some specific questionnaires, e.g. the Autonomic 
Symptom Profile [6] or the Composite Autonomic Scoring 
Scale [7], as well as Lowe modified questionnaire for diabetic 
autonomic disturbances used by Polish practitioners [8]. 
The physical examination includes pupil examination, skin 
sweating response, gooseflesh reaction, body temperature, 
and vasomotor reactions (dermographism) [5].
Physical examination is supplemented by the so-called 
‘autonomic tests’. As mentioned above, knowledge of the 
selected, autonomically-mediated physiological reflexes and 
their comparison with the reactions observed in a patient 
allows drawing conclusions about the ANS functional state.
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Table 1. Classification of factors and diseases affecting autonomic 
nervous system and causing its dysfunction [1, 5]
Examples
Drugs or 
toxins
centrally or peripherally acting α / β – sympathomimetics or 
sympatholytics
parasympathomimetics or parasympatholytics
others: tricyclic antidepressants, phenothiazines, antihistaminics, 
vincristine, cis-platin, taxol
Metals: thallium, arsenic, mercury, organophosphorus inhibitors
Diseases 
affecting 
the brain
Primary
Multiple system atrophy (Shy-Drager syndrome)
Parkinson disease
Machado-Joseph disease
Secondary
Stroke
Epilepsia
Shapiro syndrome
Neuroleptic malignant syndrome
Brain tumours
Diseases 
affecting 
the spinal 
cord 
and/or 
peripheral 
autonomic 
fibers
Congenital / 
Hereditary
Nerve growth factor deficiency
Familial amyloid neuropathy
Riley-Day syndrome (familial dysautonomia)
Metabolic
Diabetes mellitus
Chronic renal failure
Chronic liver failure
Alcohol induced
Inflammatory Guillain-Barre syndrome
Auto-
immunologic
Multiple sclerosis
Amyotrophic lateral sclerosis (Lou-Gehrig disease)
Infections
Tetanus
HIV
Chagas’ disease
Lyme disease
Diphteria
Neoplasia Lambert-Eaton paraneoplastic syndrome
Surgery
Vagotomy
Dumping syndrome
Trauma Spinal cord transection
Table 2. Selected clinical manifestations of autonomic dysfunction and 
an overview of autonomic testing methods [1, 5, 9]
Symptoms Possible testing
Cardio-
vascular
postural hypotension
supine hypertension
paroxysmal hypertension
fainting associated with voiding, 
defecation, or after long-standing
resting tachycardia / bradycardia 
episodes
Valsava manoevour
Deep breathing test
Tilt / Orthostatic test
Hand grip test
Ice water test
Face immersion test
Eyeballs oppression
Carotid sinus massage
Gastro-
intestinal
nausea, vomiting
diarrhoea / constipation
dysphagia
early postprandial distress syndrome
gastroparesis
Gastro-intestinal passage
Barium contrast image
Endoscopy
Electrogastrography
Urinary and 
sexual
urine urgency
urine retention
urine incontinence
erectile / ejaculation failure
retrograde ejaculation
priapism
Urodynamic studies
Urography
24-hour urine collection
Penile plethysmography
Respiratory
sleep apnea
snoring
Polysomnography
Eye
abnormal pupillary reaction to light
ptosis
Pharmacological evaluation 
of pupils
Schirmer tear secretion test
Sudomotor
hipohidrosis / hyperhidrosis
dyslacrimation 
Sympathetic skin  response 
Thermo-
regulation
resting hypothermia / hyperthermia
labile body temperature
Thermoregulatory sweating 
test
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Taking into account the complex clinical features of 
dysautonomia, many tests have been developed for the 
detection of specific disturbances (Tab. 2). However, most 
of them are complicated and too expensive, requiring high-
tech equipment and staff. They are considered useful only in 
advanced autonomic research, but useless in clinical practice.
Clinical and experimental autonomic tests. In common 
practice, simple cardiovascular reflexes are evaluated, 
measured by heart rate (in ECG) or blood pressure changes, 
triggered by specific provocative manoeuvers. However, there 
is no single test that could precisely evaluate the function of 
the sympathetic or parasympathetic ANS part [3, 5]. Thus, 
several tests are performed, some of which are traditionally 
perceived as targeted on the sympathetic system activity 
assessment, and others as tests evaluating predominantly 
the parasympathetic function.
The standardized test dedicated to the parasympathetic 
evaluation comprises Valsalva manoeuver, deep breathing and 
tilt (orthostatic) tests with the heart rate changes assessment 
(‘30/15 ratio’) in the ECG recordings. Furthermore, eyeballs 
oppression, carotid sinus massage or the facial immersion 
test (all causing bradycardia) are recommended as a second 
choice test [2, 5, 9].
Standard tests used for evaluation of mostly the sympathetic 
activity include: qualitative sweating tests (skin test with 
ninhydrin, iodine-starch Minor test), an orthostatic test 
with postural systolic blood pressure changes evaluation, a 
prolonged, isometric hand-grip test with changes in diastolic 
blood pressure assessment, as well as the hand immersion in 
ice water test with changes of blood pressure and heart rate 
evaluation, an assessment of postprandial blood pressure 
changes and an oculomotor test [2, 5, 10].
However, in common clinical practice, four of above-
mentioned tests (Valsalva maneuver, deep breathing test, tilt 
– orthostatic test and hand grip test) are routinely performed. 
They constitute the – so-called – ‘Ewing’s tests battery’ [2, 3, 
5], described for the first time and introduced into clinical 
practice in the 1970’s and 1980’s, and despite the passage 
of time, they are still used as a standard autonomic test set 
[11, 12, 13]. Repeatable performance of these tests as the 
ANS function monitoring, has been introduced into the 
guidelines and recommendations for practitioners in the 
management of patients with diabetes or post-myocardial 
infarction. Detailed information regarding the methodology 
and interpretation of the above-mentioned autonomic tests 
can be found in many papers, including those mentioned in 
the authors’ review [2, 3, 5].
Heart rate variability as a current common method for ANS 
evaluation. Another popular method for ANS assessment 
is the heart rate variability (HRV). Contrary to its direct 
meaning, HRV is not the investigation of changes in the heart 
rate, but a detailed analysis of differences of R-R intervals 
(also known as ‘normal-normal’ – N-N intervals) in the 
cardiac sinus rhythm, remaining under a constant autonomic 
control. The examination is based on the observation that 
R-R intervals recorded in resting ECG are not constant, but 
continuously fluctuate around the mean value, and the R-R 
variability depends on the mutual interactions between the 
sympathetic and parasympathetic part and their impact on 
the sinus node activity [3,14,15]. The HRV analysis is based 
on short (usually 5–20 minutes) or long-lasting (24-hour 
Holter) ECG recordings with subsequent time or spectral 
(frequency) domain analysis. In time domain analysis, which 
is based on the main, primary parameter, the mean R-R 
interval value, some parameters of a statistical nature are 
also obtained, e.g. standard deviation of all R-R intervals 
(SDR-R), mean value of successive absolute differences 
(MSD), the square root of the mean of the sum of the squares 
of differences between adjacent R-R intervals (rMSSD), and 
the percentage of successive R-R intervals differing more than 
50ms (pNN50). It is generally agreed that the SDR-R value 
reflects the global activity of the entire ANS, while rMSSD 
and pNN50 parameters are considered to be indicators of the 
parasympathetic tension [14, 15, 16, 17, 18, 19].
The spectral (frequency) domain analysis is based 
on the distribution of R-R intervals in relation to cyclic, 
autonomically-modulated activity of the sinoatrial node 
associated with three principal rhythms: at very low (VLF), 
low (LF) and high frequency (HF) ranges. The system of 
interconnections in many systems (including cardiovascular 
and respiratory) is the source of these oscillations. Instability 
in one interaction generates an instability in the entire system. 
The spectral HRV analysis allows for obtaining the so-called 
HRV spectrum, and determination of individual spectral 
components. The distinction of individual HRV spectral 
components allows characterization of the cyclical nature 
of the heart rate changes, hidden in a seemingly chaotic R-R 
intervals variability, based on the analysis of R-R changes 
function as a complex wave, distributing into simple waves 
of a certain frequency using the auto-regression method 
or fast Fourier transformation [2, 14, 15, 16, 17, 18, 19]. In 
short HRV recordings, three essential components may be 
distinguished: HF, LF and VLF, at high (about 0.15 – 0.4Hz), 
low (about 0.04 – 0.15Hz) and very low (about 0.003 – 0.04Hz) 
frequencies, respectively. Moreover, the ultra low frequency 
(ULF; < 0.003Hz) component may be also distinguished in 
long-lasting HRV recordings [2, 3, 14, 15, 16, 17, 18, 19].
Changes in the HRV power spectrum and its individual 
components at rest and during assessed reflexes are of 
physiological significance. The HRV total power spectrum 
is the determinant of the overall autonomic activity. The 
HF component is generally defined as a marker of isolated 
parasympathetic tension. This component is mostly respiration-
mediated and determined by the frequency of respiratory sinus 
arrhythmia, thus it is referred to be a ‘respiratory band’. The 
LF component reflects the activity of both ANS branches, 
with the sympathetic part as a primary contributor. ULF and 
VLF generally are regarded to indicate the overall activity 
of slow thermoregulatory mechanisms, chemoreceptors 
stimulations or various neuroendocrine mechanisms (e.g. the 
renin-angiotensin-aldosterone system). Similar to LF, the VLF 
measure was found to be more determined by a sympathetic 
activity. Moreover, the HRV spectrum subjected to a process 
of normalization results in two additional parameters: nLF 
and nHF. According to the generally accepted HRV guidelines, 
they are clear markers of sympathetic or parasympathetic 
tension, respectively [14, 15, 16, 17, 18, 19].
Other methods used in ANS assessment. Baroreflex sensitivity 
(BRS) testing, based on the mutual dependence between blood 
pressure and heart rate changes, is the complementary method 
of the ANS function assessment. BRS is defined as the change in 
interbeat interval (in [milliseconds]) per unit change in blood 
pressure (in [mmHg]) [20]. In this method, baroreceptors are 
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pharmacologically stimulated by administration of an agent 
raising the blood pressure that leads to reflex bradycardia 
due to the parasympathetic stimulation. The baroreceptor 
response can be also tested using its decompression, achieved 
after administration of a strong, hypotensive agent (e.g. sodium 
nitroprusside or nitroglycerine). The baroreflex sensitivity 
consists in determination of the slope of the linear regression 
between beat-to-beat systolic blood pressure values and R-R 
intervals values [3, 20, 21]. There is also a more advanced 
‘sequence method’ in which continuous blood pressure and 
R-R recordings are scanned for sequences in which systolic 
blood pressure and R-R intervals concurrently increase or 
decrease for at least three following beats, and the relationship 
defining those changes also indicates the baroreflex sensitivity 
[3, 20, 21].
So far, this paper has mentioned clinical, indirect methods 
of ANS assessment, mostly based on cardiovascular reflexes. 
Currently, there are also tests providing a direct measurement 
of peripheral autonomic afferent and efferent traffic to 
muscle and skin using the microneurography technique 
[22, 23]. Recording of efferent discharge in skin and muscle 
C-fibres is referred to as ‘muscle sympathetic nerve activity’ 
(MSNA), in which the electrode tip penetrates the muscle 
nerve fascicles, or ‘skin sympathetic verve activity (SSNA), 
in which recordings are taken from skin nerve fascicles.
Sympathetic microneurography seems to be useful in 
demonstrating autonomic dysfunctions concerning the 
thermoregulation or blood pressure control [24]. Recordings 
of afferent discharge from cutaneous and muscle spindle are 
also performed to the analyze the neural mechanisms of 
motor control. Analysis of afferent discharges from cutaneous 
mechanoreceptors reveals mechanoreception dysfunctions, 
such as vibrotactile sensation or paresthesia. Recordings of 
afferent discharges from nociceptors in muscle and skin 
indicate valuable objective signals related to pain and other 
sensations, such as itch [24].
Current and future, possible laboratory assays estimating 
autonomic activity – Plasma noradrenaline measurement. 
Assessment of the ANS function using the methods 
described above is difficult and time-consuming. Thus, 
there are ongoing studies aimed at finding some reliable 
laboratory parameters indicating autonomic activity. Plasma 
acetylcholine measurement as a marker of parasympathetic 
tension is impractical because the substance is highly labile 
and quickly decomposed by acetylcholinesterase, and thus 
cannot be quantified [3]. In contrast, the sympathetic activity 
is usually assessed by the plasma noradrenaline concentration 
assay, according to the assumption adopted in the 1980’s that 
it reflects the ‘overall’ sympathetic activity [25, 26]. Although 
the measurement provides some useful information, it has 
also some significant limitations, mostly associated with 
the fact that circulating NA represents only a fraction of 
the amount of the neurotransmitter package secreted from 
nerve terminals. Moreover, the plasma noradrenaline level 
is influenced by its clearance, metabolism and uptake from 
the circulating blood. Finally, the plasma NA measurement 
does not allow discrimination between the central (increased 
secretion) and peripheral (reduced clearance) mechanism of 
increase of that neurotransmitter, nor for differentiation of 
decreased NA level, due to diminished central noradrenergic 
structures activity or increased peripheral clearance [27]. 
Hence, the noradrenaline spillover rate measurement has 
been proposed as a better surrogate for sympathetic tension 
determination, instead of measurement of total, static serum 
noradrenaline concentration.
The metabolic clearance rate method, based on noradrenaline 
isotope plasma dilution, allows calculation of the confounding 
influence of plasma NA clearance, in which a small, radio-
labelled amount of NA is administrated intravenously. The 
substance is subject to tissue uptake, which is subtracted from 
the plasma NA level. The total, remaining radio-labeled and 
intact NA level assay allows determination of the additional 
neurotransmitter amount released from neuroeffector 
junctions [3]. Noradrenaline spillover measurement tests the 
rate at which the released norepinephrine enters plasma, rather 
than the rate of release of norepinephrine from sympathetic 
terminals. Since the overflow of released norepinephrine 
to plasma is influenced by the parallel neuronal reuptake, 
the performance of tests of norepinephrine reuptake, 
together with the metabolic clearance rate measurements, 
provides comprehensive information, e.g. answering the 
question whether the higher NA spillover is due to increased 
norepinephrine release, or its deficient reuptake [28].
Moreover, radiotracer-derived measurements of the 
appearance rate of noradrenaline in plasma from individual 
organs may also be a technique complementary to 
microneurography. That method cannot access sympathetic 
nerves of internal organs. The relationship between the 
sympathetic nerve firing in a selected organ (e.g. heart or 
kidneys) and the noradrenaline overflow rate, estimated in 
regional blood samples, justifies using regional noradrenaline 
spillover as a surrogate for nerve traffic measurements [29].
Assay of plasma neuropeptides co-released with 
noradrenaline or acetylcholine. Noradrenergic, sympathetic 
fibres, as well as cholinergic, parasympathetic fibres, also 
demonstrate the ability to release some non-cholinergic 
non-adrenergic (NANC) neurotransmitters, apart from 
noradrenaline or acetylcholine, respectively. Neuropeptide 
Y (NPY) is one of them, a substance that has been found 
in sympathetic neurons, co-stored and co-released with 
catecholamine [30, 31]. NPY is a polypeptide consisting of 
36 amino acid units, presenting a high homology with the 
pancreatic polypeptide. NPY immunoreactivity neurons 
have been found in both the central and peripheral nervous 
systems. The highest brain NPY content was found in 
supraoptic and paraventricular hypothalamic and thalamic 
nuclei, and in medulla oblongata neurons that belong to 
the central sympathetic structures, as mentioned in the 
Introduction [32, 33]. The NPY impact on sympathetic 
neurons is ambiguous. There are reports of the inhibitory 
NPY role in central sympathetic activity, and that the 
compound is regarded to diminish stress-related sympathetic 
consequences [34], thus exerting an anxiolytic effect.
In contrast, there is a general agreement, that NPY has an 
excitatory effect in relation to the peripheral sympathetic 
nervous system, enhancing its activity synergistically with 
catecholamines and glucocorticoids [35]. NPY-containing 
neurons are located in sympathetic ganglia and in tissues 
receiving abundant sympathetic innervation (blood 
vessels, heart, spleen, kidneys, digestive, respiratory and 
urogenital tracts). Thus, peripherally, NPY is co-responsible 
for vasoconstriction (producing a strong effect resistant to 
alpha blockade), vascular smooth muscle cells proliferation, 
stimulated hyperlipidaemia and hyperglycaemia. Moreover, 
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NPY participates in neointimal formation, macrophage 
infiltration of the vascular injury, and subsequent 
atherosclerotic plaque. NPY is also reported to cause increase 
of the renal artery resistance and decrease in renal blood flow. 
Together with the RAA system activated because of the high 
sympathetic tension, NPY contributes to the development 
of hypertension. High plasma NA level has been found 
in patients with some clinical conditions associated with 
sympathetic overactivity, such as congestive heart failure or 
myocardial ischaemia [35, 36]. Considering the physiological 
premises listed above, the concept of determining plasma 
NPY concentration as a laboratory marker of sympathetic 
activity seems to be justified.
Parasympathetic efferent fibres, in turn, demonstrate co-
secretion of another neuropeptide – the vasoactive intestinal 
peptide (VIP). VIP is a 28-amino acid polypeptide that was 
first demonstrated to be a potent vasodilatatory agent in the 
duodenum. However, further studies revealed that VIP is 
distributed in the peripheral innervation of various tissues 
and exhibits multiple effects. Apart from vasodilatation 
(mostly observed in intestinal, hepatic, coronary and 
pulmonary vessels), it relaxes the lower oesophageal sphincter 
and sphincter of Oddi, as well as bronchial smooth muscle, 
facilitates intestinal and pancreatic secretion, but inhibits 
gastric secretion, and promotes the secretion of both insulin 
and glucagon in a glucose-dependent manner. VIP also plays 
an immunomodulatory role, and inhibits the macrophage 
release of proinflammatory nitric oxide or tumour necrosis 
factor and promotes the production of anti-inflammatory 
cytokines, such as interleukin-10 [37].
VIP-immunoreactive neurons are also broadly distributed 
in the central nervous system. They were found in the 
limbic area and in the periventricular grey matter of the 
diencephalon. They are also located in nucleus mamillaris 
lateralis, but sparse in the preoptic area, supraoptic nucleus 
and the paraventricularis nucleus [32, 38]. Numerous reports 
of VIP and Ach co-transmission were published in 1980’s and 
1990’s [39, 40], and that concept is commonly accepted today 
[32]. Thus, similar to NPY for the sympathetic branch, VIP 
is proposed to be the marker of parasympathetic activity.
SUMMARY
Neuropeptides playing the role of co-transmitters in 
peripheral tissues seem to be the next, potential laboratory 
markers of the ANS activity, and there is an increasing number 
of papers focusing on the NPY and VIP measurements 
used to evaluate the autonomic activity. One of these is 
the study by El-Sayed et al. [41] which aimed to assess the 
cardiac autonomic function in patients with systemic lupus 
erythematosus and juvenile idiopathic arthritis (JIA) using 
serum levels of NPY and VIP as indicators of sympathetic 
and parasympathetic functions, respectively. Use of that 
method confirmed the autonomic neuropathy in both lupus 
and JIA patients (even in the absence of relevant symptoms), 
and concluded that serum autonomic neuropeptides (NPY 
and VIP) may be valuable markers of autonomic function 
and should be monitored in these patients [41].
Neuropeptides as novel salivary markers of ANS activity. 
Studies using saliva levels of the same neuropeptides 
involved in autonomic saliva secretion control are also 
worth mentioning. That concept is based on anatomical and 
physiological aspects of saliva secretion. VIP and NPY are 
important NANC mediators controlling saliva production, 
that may be found in the fluid. Some immunohistochemistry 
studies demonstrated high density of VIP-containing 
neurons around the ducts and blood vessels of the minor 
salivary glands in humans [42, 43]. However, in humans, 
the saliva is mostly secreted by submandibular and parotid 
glands. In contrast to the minor salivary glands, they receive 
both sympathetic and parasympathetic innervation [44, 45]. 
Moreover, it was shown that saliva fluid secretion is mediated 
by a primarily cholinergic mechanism, while the production 
of saliva proteins (alpha-amylase) is under the control of both 
cholinergic and adrenergic mechanisms [46]. On the other 
hand, some animal studies revealed that both mucins and 
water production in sublingual salivary glands is controlled 
primarily by parasympathetic fibres (Ach, VIP) [40].
Taking into account the premises described above, 
few studies have been published so far using the saliva 
determination of both VIP and NPY as markers of the ANS 
activity [47, 48, 49]. However, that novel method is not widely 
used at present and it still requires further development. There 
are some objections, particularly concerning anatomical 
differences between the determinants of the salivary 
glands innervation in humans and animals, causing partial 
incompatibility in research on animals and humans. There 
are also differences in the participation of individual salivary 
glands in the saliva production in animals and humans 
[50]. Furthermore, due to the complex autonomic control of 
individual salivary glands, there is a tendency for VIP or NPY 
determination from a single, selected salivary gland, and not 
in the total saliva. However, it appears that the unique method 
using saliva as a medium for the determination of VIP / 
NPY as markers of the ANS activity is very interesting, and 
for this reason, studies on that subject should be continued.
CONCLUSIONS
Due to the existence of various clinical entities associated with 
primary or secondary autonomic dysfunctions manifested 
by complex, multisystem symptoms, the assessment of 
autonomic nervous system activity seems to be extremely 
important. However, from the practical point of view, such 
an assessment is difficult and predominantly indirect, based 
on the analysis of cardiovascular reflexes controlled by 
sympathetic and parasympathetic fibres. The classical, clinical 
functional ANS assessment involves both anamnesis and 
physical examination aimed at the diagnosis of dysautonomia, 
together with a set of the so-called, Ewing’s autonomic tests: 
Valsalva manoeuver, orthostatic tilt test, deep breathing test, 
isometric hand grip test. Short and long (24-hour) ECG 
recordings, with a subsequent time- and spectral (frequency) 
heart rate variability analysis, are also performed. Other, 
complementary methods used in scientific research rather 
than in routine clinical ANS function assessment, include: 
baroreflex sensitivity testing or direct registration of the 
electrical activity of the autonomic fibres – microneurography.
Currently, a laboratory-based ANS activity assessment 
is practically impossible, except for the ambiguous plasma 
NA measurement, correlated with the sympathetic 
activity. However, many studies concerning the NANC 
neurotransmitters (especially some neuropeptides, e.g. NPY 
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or VIP), co-released with the NA or Ach in the autonomic 
fibres, are carried out. These co-transmitters, also assayed 
in the plasma, are regarded to be good, potential indicators 
of the ANS activity. Moreover, according to some research, 
NPY and VIP levels reflecting the autonomic tension may 
be also measured in saliva. Some preliminary studies on the 
applicability of NPY and VIP as laboratory markers of the 
ANS activity are promising, and their further development 
and increasing significance can be expected.
REFERENCES
1. Mathias CJ. Autonomic diseases: clinical features and laboratory 
evaluation. J Neurol Neurosurg Psychiatry. 2003; 74(Suppl. III): 31–41.
2. Rydlewska A, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, 
Jankowska EA, Ponikowski P. Ocena aktywności autonomicznego 
układu nerwowego związanej z odruchową regulacją układu sercowo-
naczyniowego i oddychania. Kardiol Pol. 2010; 68(8): 951–957 (in Polish).
3. Zygmunt A, Stańczyk J. Methods of evaluation of autonomic nervous 
system function. Arch Med Sci. 2010; 6(1): 11–18.
4. Januszewicz W, Szczepańska-Sadowska E, Januszewicz A, Prejbisz 
A. Neurogenne aspekty nadciśnienia tętniczego. Nadciśn Tętn. 2008; 
12(1): 1–11 (in Polish).
5. Mariańska K, Koszewicz M. Kliniczna ocean układu autonomicznego. 
Pol Przegl Neurol. 2008; 4(2): 51–57 (in Polish).
6. Suarez GA, Opfer-Gehrking KP, Offord MS, Atkinson EJ, O’Brien PC, 
Low PA. The autonomic Symptom Profile. A new instrument to assess 
autonomic symptoms. Neurology 1999; 52(3): 523–528.
7. Low PA. Clinical autonomic disorders: evaluation and management. 2nd 
ed. Lippincott-Raven Publishers, Philadelphia; 1997: 3–175.
8. Zakrzewska-Pniewska B. Autonomiczny układ nerwowy w cukrzycy. 
Aktualn Neurol. 2004; 4(2): 116–121 (in Polish).
9. Budrewicz S. Standardowe badania kliniczne czynności autonomicznych 
– układ przywspółczulny. In: Podemski R. (ed.). Diagnostyka 
autonomicznego układu nerwowego I zaburzeń snu. Ed. 1. Wrocław, 
Wydawnictwo Medyczne Urban & Partner; 2006: 5–22 (in Polish).
10. Budrewicz S. Standardowe badania kliniczne czynności autonomicznych 
– układ współczulny. In: Podemski R. (ed.). Diagnostyka autonomicznego 
układu nerwowego I zaburzeń snu. Ed. 1. Wrocław, Wydawnictwo 
Medyczne Urban & Partner; 2006; 23–33 (in Polish).
11. Ewing DJ. Cardiovascular reflexes and autonomic neuropathy. Clin Sci 
Mol Med. 1978; 55(4): 321–327.
12. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic 
neuropathy. Br Med J. 1982; 285(6346): 916–918.
13. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular 
autonomic function tests: 10 years experience in diabetes. Diabetes 
Care 1985; 8(5): 491–498.
14. Malik M (ed.). Heart rate variability. Standards of measurement, 
physiological interpretation, and clinical use. Task Force of The 
European Society of Cardiology and The North American Society of 
Pacing and Electrophysiology. Eur Heart J. 1996; 17(3): 354–381.
15. Berntson GG, Bigger JT JR, Eckberg DL, Grossman P, Kaufmann PG, 
Malik M, et al. Heart rate variability: origins, methods, and interpretive 
caveats. Psychophysiology 1997; 34(6): 623–648.
16. Sztajzel J. Heart rate variability: a noninvasive electrocardiographic 
method to measure the autonomic nervous system. Swiss Med Wkly. 
2004; 134 (35–36): 514–522.
17. Acharya UR, Joseph KP, Kannathal N, Lim CM, Suri JS. Heart rate 
variability: a review. Med Bio Eng Comput. 2006; 44(12): 1031–1051.
18. Karim N, Hasan JA, Ali SS. Heart rate variability – a review. J Basic 
Appl Sci. 2011; 7(1): 71–77.
19. ChuDuc H, NguyenPhan K, NguyenViet DA. Review of Heart Rate 
Variability and its Applications. APCBEE Procedia 2013; 7: 80- 85.
20. Swenne CA. Baroreflex sensitivity: mechanisms and measurement. 
Neth Heart J. 2013; 21(2): 58–60.
21. La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: measurement 
and clinical implications. Ann Noninvasive Electrocardiol. 2008; 13(2): 
191–207.
22. Gandevia SC, Hales JP. The methodology and scope of human 
microneurography. J Neurosci Methods. 1997; 74(2): 123–136.
23. Vallbo AB, Hagbarth KE, Wallin BG. Microneurography: how the 
technique developed and its role in the investigation of the sympathetic 
nervous system. J Appl Physiol. 2004; 96(4): 1262–1269.
24. Mano T, Iwase S, Toma S. Microneurography as a tool in clinical 
neuropsysiology to investigate peripheral neural traffic in humans. 
Clin Neurophysiol. 2006; 117(11): 2357–2384.
25. Wallin BG, Sundlof G, Eriksson BM, Dominiak P, Grobecker H, 
Lindblad LE. Plasma noradrenaline correlates to sympathetic muscle 
nerve activity in normotensive man. Acta Physiol Scand. 1981; 111(1): 
69–73.
26. Goldstein DS, McCarty R, Polinsky RJ, Kopin IJ. Relationship between 
plasma norepinephrine and sympathetic neural activity. Hypertension 
1983; 5(4): 552–559.
27. Sinski M, Lewandowski J, Abramczyk P, Narkiewicz K, Gaciong Z. 
Why study sympathetic nervous system? J Physiol Pharmacol. 2006; 
57(Suppl. II): 79–92.
28. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. 
Assessment of human sympathetic nervous system activity from measure-
ments of norepinephrine turnover. Hypertension 1988; 11(1): 3–20.
29. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. 
Sympathetic nerve activity and neurotransmitter release in humans: 
translation from pathophysiology into clinical practice. Acta Physiol 
Scand. 2003; 177(3): 275–284.
30. Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, 
et  al. Neuropeptide Y (NPY) – like immunoreactivity in peripheral 
noradrenergic neurons and effects of NPY on sympathetic function. 
Acta Physiol Scand. 1982; 116(4): 477–480.
31. Lundberg JM, Franco-Cereceda A, Hemsen A, Lacroix JS, Pernow J. 
Pharmacology of noradrenaline and neuropeptide tyrosine (NPY)-
mediated sympathetic cotransmission. Fundam Clin Pharmacol. 1990; 
4(4): 373–391.
32. Burnstock G. Cotransmission in the autonomic nervous system. In: Buijs 
RM and Swaab DF, Eds. Handbook of Clinical Neurology. Autonomic 
Nervous System. Vol 117 (3rd series), Elsevier; 2013: 23–35.
33. Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease 
and repair. Exp Neurol. 2012; 238(2): 265–272.
34. Heilig M. The NPY system in stress, anxiety and depression. 
Neuropeptides 2004; 38(4): 213–224.
35. Kuo LE, Zukowska Z. Stress, NPY and vascular remodeling: implications 
for stress-related diseases. Peptides 2007; 28(2): 435–440.
36. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal 
soldier. Cell Mol Life Sci. 2003; 60(2): 350–377.
37. Igarashi H, Fujimori N, Ito T, Nakamura T, Oono T, Nakamura K, et al. 
Vasoactive intestinal peptide (VIP) and VIP receptors – elucidation of 
structure and function for therapeutic applications. Int J Clin Med. 
2011; 2(4): 500–508.
38. Petkó M, Ihionvien M. Distribution of substance P, vasoactive intestinal 
polypeptide and serotonin immunoreactive structures in the central 
nervous system of the lizard, Lacerta agilis. J Hirnforsch. 1989; 30(4): 
415–423.
39. Costa M, Furness JB, Gibbins IL, Morris JL, Bornstein JC, Llewellyn-
Smith IJ,  et al. Colocalization of VIP with other neuropeptides and 
neurotransmitters in the autonomic nervous system. Ann N Y Acad 
Sci. 1988; 527: 103–109.
40. Culp DJ, Richardson LA. Regulation of mucous acinar exocrine 
secretion with age. J Dent Res. 1996; 75(1): 575–580.
41. El-Sayed ZA, Mostafa GA, Aly GS, El-Shahed GS, Abd El-Aziz MM, El-
Emam SM. Cardiovascular autonomic function assessed by autonomic 
function tests and serum autonomic neuropeptides in Egyptian children 
and adolescents with rheumatic diseases. Rheumatology 2009; 48(7): 
843–848.
42. Konttinen YT, Hukkanen M, Kemppinen P, Segerberg M, Sorsa T, 
Malmstrom M, et al. Peptide-containing nerves in labial salivary glands 
in Sjorgen’s syndrome. Arthritis Rheum. 1992; 35(7): 815–820.
43. Feher E, Zelles T, Nagy G. Immunocytochemical localization of 
neuropeptide-containing nerve fibres in human labial glands. Arch 
Oral Biol. 1999; 44(Suppl. 1): S33-S37.
44. Ekstrom J, Asztely A, Tobin G. Non-adrenergic, non-cholinergic 
influences on parotid acinar degranulation in response to stimulation of 
the parasympathetic innervation in the anaesthetized rat. Exp Physiol. 
1996; 81(6): 935–942.
45. Proctor GB, Carpenter GH. Regulation of salivary gland function by 
autonomic nerves. Auton Neurosci. 2007; 133(1): 3–18.
46. Jensen JL, Brodin P, Berg T, Aars H. Parotid secretion of fluid, amylase 
and kallikrein during reflex stimulation under normal conditions and 
after acute administration of autonomic blocking agents in man. Acta 
Physiol Scand. 1991; 143(3): 321–329.
47. Dawidson I, Blom M, Lundeberg T, Theodorsson E, Angmar-Mansson 
B. Neuropeptides in the saliva of healthy subjects. Life Sci. 1997; 60(4–5): 
269–278.
48. Naito T, Itoh H, Takeyama M. Effects of hange-koboku-to on 
neuropeptide levels in human plasma and saliva. Biol Pharm Bull. 
2003; 26(11): 1609–1613.
49. Satoh Y, Itoh H, Takeyama M. Effects of bakumondoto on neuropeptide 
levels in human saliva and plasma. J Trad Med. 2009; 26(3): 122–130.
50. Humphrey SP, Williamson RT. A review of saliva: normal composition, 
flow and function. J Prosthet Dent. 2001; 85(2): 162–169.
68
